Audit: QRS - Magnesium Malate for Health & Longevity

Audit conducted on 23/08/2026 03:33 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	81
Failed	0
N/A	12
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Verified item by item against the ER: protocol values (ER l.366, 372, 376), time-to-effect (ER l.415), benefit and risk tier headings (ER l.151-237, 259-303), contraindications (ER l.343-346), interactions (ER l.323-339), biomarker table (ER l.441-451) and qualitative markers (ER l.455-460) all map literally.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Speculative-tier items retain the ER’s hedged framing (“Preferential delivery of magnesium to skeletal muscle”, “malate-driven support for cellular energy production”); no ER hedge is dropped in favour of a firmer word.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Thresholds and conditions are carried at ER strength: “unless nephrologist-supervised” (QRS l.542 = ER l.343), “monitoring warranted with spironolactone” (QRS l.556 = ER l.329).
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Benefit-modifying and risk-modifying factors from ER l.242-252 and l.308-318 are not surfaced as contraindications, interactions or side effects.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, author names, NCT identifiers or brand names appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind are present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Matches the ER’s measured, deflationary framing that the magnesium, not the malate, carries the evidence (ER l.482-486).
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Expert and data-driven throughout; tiers and thresholds are given without alarm or promotion.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is presented as evidence and convention (“Conventional, on the energy rationale”, QRS l.472), not as instruction.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	Protocol and monitoring cells state what is done and observed rather than prescribing to a reader.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No “recommend”, “advise”, or “should” constructions in the QRS’s own voice.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person address; the only imperative text is the fixed template disclaimer in the footer.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms carried from the ER are expanded where the ER expands them (QRS l.624 “eGFR (estimated glomerular filtration rate)”, l.668 “HbA1c (glycated haemoglobin)”).
2.8	Information is presented in a concise and very compact manner	🟢	Every cell and list item is a compressed phrase; no sentence exceeds one line of content.
2.9	It DOES NOT address the reader directly	🟢	Confirmed — no “you” or “your” in any populated span.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Framing assumes an active user weighing dose, split dosing, biomarker targets and interaction windows.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Protocol, monitoring cadence and nine-marker panel presuppose willingness to test and titrate.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Content depth (red-cell magnesium targets, eGFR thresholds, 2-4 h chelation separation) is well beyond general-population material.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-a-glance states the benefit concentrates in the depleted, which is the signal difference that matters to this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	No occurrence of “anti-aging” in the file; page title and header use “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Clinical register throughout (“osmotic diarrhoea”, “hypermagnesaemia”, “atrioventricular block”); the plain terms “loose stools” and “blood sugar” occur only in the at-a-glance, where item 7.4 requires plain language, and are the ER Conclusion’s own wording (ER l.482, 486).

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed headings present verbatim: “Protocol” (l.440), “Time to effect” (l.477), “Benefits” (l.519), “Risk & Side Effects” (l.571), “Monitoring” (l.590), “Qualitative Assessment” (l.709), “Contraindications” (l.539), “Key Interactions” (l.550), tier labels High/Medium/Low/Speculative, and Marker/Target/Why (l.594-596).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 67 data-qrs-var spans are present: 5 header/at-a-glance, 9 action, 9 time, 4 benefits, 2 gates, 4 risks, 27 marker, 1 cadence, 6 qualitative.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Unaddressed template spans are intact and unmodified (l.423 website="evidence_review", l.426 website="audit", l.434 website="full_review"); CSS, footer disclaimer and override stylesheet link are unchanged.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section relevant to the QRS is empty; every mapped ER section carries content.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	ER bold labels are reused verbatim: “Standard dose”, “Single versus split dosing”, “Best time of day” (ER l.366, 376, 372) and all nine interaction labels (ER l.323-339).
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	No label is invented; every label traces to an ER bullet label or ER heading.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No 🟩/🟥/🟨 or any other emoji in the file; tiering is conveyed by bold labels and CSS colour only.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Each section is condensed rather than transcribed: benefit and risk tiers are single comma-joined lines, interaction bullets are stripped to label plus key fact, and biomarker “Why” cells are reduced to short phrases.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	The metadata comment opens on l.2, immediately after <!doctype html> on l.1, and precedes all other content.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- on l.3 and closing --- on l.13; the preceding descriptive text sits outside the block.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment and not duplicated by any rendered element.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All values trimmed; only duration: "00:03" is quoted, which is required because the value contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: magnesium_malate_2026-0823-0003_Opus_ER.md (l.4) matches the source ER.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.7.02 (l.5) matches the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-0823-0228 (l.6) is in YYYY-MMDD-HHMM form.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Opus (l.7).
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	Single word, no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Opus 5 (l.8).
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	Nickname plus version number only, no additional qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename: magnesium_malate_2026-0823-0003_Opus_QRS.html (l.9) matches the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	l.22 reads “Magnesium Malate for Health & Longevity - Quick Reference Sheet”, matching canonical_topic (ER l.8) with the ampersand entity-encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	l.417 reads “Magnesium Malate for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	l.421 reads 08/23/2026, the MM/DD/YYYY form of qrs_creation_date 2026-0823-0228.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	l.425 reads “Opus 5”, matching qrs_creator_ai_fullname.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header carries only title and the template subline; no badge, version stamp, alternate-names line, audit date or variant marker.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses the ER Conclusion (ER l.482-486) into the magnesium-versus-malate split, the outcomes, the untested malate claims and the dose-limiting and kidney constraints.
7.2	[at_a_glance] is no longer than 60 words	🟢	59 words, counted programmatically after HTML-entity unescaping.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause traces to a distinct Conclusion passage: ER l.482 (magnesium not malate; blood pressure, blood sugar, depletion; stroke, heart failure, death rates), l.484 (malate untested in humans), l.486 (loose stools, kidney danger).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	Plain-language throughout — “blood sugar” not HbA1c, “loose stools” not osmotic diarrhoea, “less stroke and heart failure” not relative risks; no acronyms.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years, sample sizes or p-values.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No effect sizes, relative risks or confidence intervals.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All four items derive from the ER’s “Populations who should avoid Magnesium Malate” list under Key Interactions & Contraindications (ER l.341-346).
8.2	[stop_items] represent the Contraindications from the ER	🟢	All four ER avoid-populations are represented, one-for-one (QRS l.542-545).
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Each item is a separate <li> inside the [stop_items] span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Mechanistic tails are stripped — ER’s “where magnesium can precipitate weakness” (l.344) and the “(a stalled bowel)” gloss (l.346) are removed; no dash-trailing clauses remain.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Decision-relevant qualifiers are kept: “stage 4-5 (eGFR below 30 mL/min/1.73 m²)”, “below 50 beats per minute”, “acute severe”, “unless nephrologist-supervised”.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s Key Interactions & Contraindications section uses no ranking notation inside parentheses.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	N/A	The section is not empty; the ER names four populations that should avoid the intervention.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All nine items derive from the ER Key Interactions & Contraindications bullets (ER l.323-339).
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Nine interaction bullets present; none duplicates a contraindication.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Each item is a separate <li> inside the [caution_items] span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Reduced to bold label plus key fact (e.g. “Levothyroxine: 4 h separation; thyroid rechecked”); no rationale, citations or dash-trailing clauses.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drug lists and thresholds are preserved in shortened form: “(doxycycline, ciprofloxacin)”, “(alendronate, risedronate)”, “(amlodipine, losartan)”, “(milk of magnesia)”, “(omeprazole)”, “zinc above 140 mg/day”.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s Key Interactions & Contraindications section uses no ranking notation inside parentheses.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	N/A	The section is not empty; the ER lists nine interaction bullets.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	Values are taken from the ER Therapeutic Protocol section (ER l.364-386).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose, split-versus-single dosing and time of day are the three actionable levers in that section; the remaining bullets are contextual (half-life, genetics, sex, age, comorbidity).
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER Therapeutic Protocol section supplies three or more distinct actionable aspects; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine action cells carry ER-derived content: ER l.366 (dose and 350 mg/day cap), l.376 (split dosing, fractional absorption, tolerability), l.372 (morning/early afternoon, evening without penalty).

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Blood pressure/glycaemic (4-12 weeks), sleep or muscle comfort (1-3 weeks) and red-cell magnesium (8-12 weeks) are taken from ER l.415.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered highest-magnitude first: the High-tier blood-pressure and glycaemic benefits, then the Medium/Low subjective changes, then the status biomarker plateau.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies four distinct time-to-effect aspects; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine time cells carry ER-derived content, with the subs sourced from ER l.415 and the 12-week recheck at ER l.439.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information under Practical Considerations.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All four tiers mirror the ER Expected Benefits headings (ER l.151-237).
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated (QRS l.521-532).
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each tier is a comma-joined list of ER benefit headings with no magnitudes, mechanisms or citations attached.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content survives; the ER’s “⚠️ Conflicted” markers and effect figures are stripped as required.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers carry items in the ER Expected Benefits section.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All four tiers mirror the ER Potential Risks & Side Effects headings (ER l.259-303).
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated (QRS l.573-584).
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each tier is a comma-joined list of ER risk headings; frequencies, hazard ratios and study attributions are absent.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	The ER’s glosses such as “(an excess of magnesium in the blood)” (ER l.271) are stripped, and no frequency figures are carried through.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four risk tiers carry items in the ER Potential Risks & Side Effects section.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Table is built from the ER Monitoring Protocol & Defining Success biomarker table (ER l.441-451).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All nine ER biomarkers are present in ER order with matching targets: red blood cell magnesium, serum magnesium, eGFR, serum potassium, serum calcium (albumin-corrected), 25-hydroxyvitamin D, HbA1c, hs-CRP, home blood pressure.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	l.703 carries “Baseline, 12 weeks, then every 6-12 months; within 4 weeks of a dose increase, new kidney-affecting drug or declining kidney function”, matching ER l.439.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Items derive from the qualitative marker list in the ER Monitoring Protocol & Defining Success section (ER l.455-460).
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER qualitative markers are present in ER order (QRS l.712-728).

Issues 23/08/2026 03:33

Pass rate 100.00%. No issues found.

Issues 23/08/2026 03:26

1. 1.1 — “elemental” dropped from dose cap: [action_1_sub] (line 450) reads “total supplemental intake at or below 350 mg/day”, but the ER (Therapeutic Protocol, Standard dose) caps “total supplemental elemental magnesium”; without “elemental” the cap contradicts the “1,250-2,000 mg daily” compound dose in the same cell.

Fixes 23/08/2026 03:26

1. 1.1 — “elemental” restored in dose cap: [action_1_sub] changed from “total supplemental intake at or below 350 mg/day” to “total supplemental elemental magnesium usually at or below 350 mg/day”, matching the ER’s Therapeutic Protocol wording and removing the contradiction with the compound dose in the same cell.

Issues 23/08/2026 03:17

1. 2.5 — Imperative “monitor” in caution item: The antihypertensives caution item at line 556 ends “additive lowering; monitor with spironolactone”, a bare imperative that advises rather than presents; ER line 329 frames it as “serum magnesium warrants monitoring when both are used”.

Fixes 23/08/2026 03:17

1. 2.5 — Imperative “monitor” in caution item: Reworded the antihypertensives caution item from “additive lowering; monitor with spironolactone” to “additive lowering; monitoring warranted with spironolactone”, matching the ER’s presentational framing.

Issues 23/08/2026 03:14

1. 9.5 — OTC example drug lists dropped: The “Over-the-counter medications” caution item (QRS line 557) drops both parenthetical example drug lists from the ER bullet (ER line 331) — “(milk of magnesia)” and “(omeprazole, esomeprazole)” — instead of shortening them, leaving the reader without a named example for either stacking agent or depleting agent.

Fixes 23/08/2026 03:14

1. 9.5 — OTC example drug lists restored: Added the ER’s parenthetical examples back to the “Over-the-counter medications” caution item, from “antacids and magnesium laxatives stack dose; proton pump inhibitors deplete” to “antacids and magnesium laxatives (milk of magnesia) stack dose; proton pump inhibitors (omeprazole) deplete”.

Issues 23/08/2026 03:07

1. 4.5 — Key Interactions gate overflows page: The nine caution_items at lines 552-562 run 106-183 characters each (about 25 wrapped lines in a half-width gate), consuming roughly half the A4 column height and forcing Monitoring and Qualitative Assessment beyond one page; several protocol subs, benefit and risk lines also wrap more than the per-section budget allows.

Fixes 23/08/2026 03:07

1. 4.5 — Key Interactions gate condensed: Tightened all nine caution_items to their actionable core (e.g. “Separation of at least two hours before or four hours after” → “2 h before, 4 h after”; the antacid/laxative/proton-pump entry cut from 183 to 105 characters), reducing the gate from roughly 25 wrapped lines to 18 while keeping every ER bold label verbatim and every threshold, drug exemplar and time window intact.
2. 4.5 — Protocol and cadence trimmed: Shortened action_1_sub (“total supplemental intake usually at or below 350 mg/day” → “total supplemental intake at or below 350 mg/day”) and monitoring_cadence (“Baseline, recheck at 12 weeks … within four weeks” → “Baseline, 12 weeks … within 4 weeks”) to remove a wrapped line from each.

Issues 23/08/2026 03:00

1. 9.5 — Dropped OTC example-drug lists: The “Over-the-counter medications” item at line 557 drops both ER parentheticals entirely — “(milk of magnesia)” and “(omeprazole, esomeprazole)” from ER line 331 — instead of trimming them.
2. 1.3 — Digoxin framed as a hazard: Line 560 lists digoxin flat alongside cisplatin, amphotericin B, aminoglycosides and ciclosporin, implying a shared hazard, whereas ER line 337 states that correcting a magnesium deficit is “protective rather than hazardous” for digoxin.

Fixes 23/08/2026 03:00

1. 9.5 — Restored OTC example-drug lists: Re-added the two ER parentheticals to the “Over-the-counter medications” interaction item — “(milk of magnesia)” after magnesium laxatives and “(omeprazole, esomeprazole)” after proton pump inhibitors.
2. 1.3 — Digoxin no longer framed as a hazard: Rewrote the “Other intervention interactions” item from a flat list ending “ciclosporin, digoxin” to “ciclosporin cause magnesium wasting; low magnesium worsens digoxin toxicity”, matching the ER’s protective-rather-than-hazardous framing.

Issues 23/08/2026 02:53

1. 4.3 — Biomarker label paraphrased: marker_3_name (QRS line 624) reads “eGFR (kidney filtration rate)” where the ER’s biomarker label is “eGFR (estimated glomerular filtration rate)” (ER line 445).

Fixes 23/08/2026 02:53

1. 4.3 — Biomarker label paraphrased: Restored the ER’s own gloss for marker_3_name, changing “eGFR (kidney filtration rate)” to “eGFR (estimated glomerular filtration rate)”.

Issues 23/08/2026 02:47

1. 4.5 — Sheet overruns one A4 page: The rendered sheet is roughly twice the A4 budget; the Key Interactions gate (lines 553-561) wraps to about 28 lines and the nine-row Monitoring table (lines 600-698) to about 20, with at-a-glance, benefits, risks and the qualitative list uncondensed on top.

Fixes 23/08/2026 02:47

1. 4.5 — Key Interactions gate condensed: Trimmed the nine interaction items to their key facts while keeping every ER label verbatim and at least one named drug per parenthetical (e.g. “doxycycline, minocycline, ciprofloxacin, levofloxacin” to “doxycycline, ciprofloxacin”; “beetroot or nitrate products, omega-3 fatty acids” to “nitrates, omega-3”).
2. 4.5 — Monitoring rationales shortened: Reduced all nine “Why” cells to single-line statements (e.g. “Low magnesium causes potassium wasting that will not correct until magnesium is restored” to “Low magnesium drives potassium wasting”), shortened the eGFR marker name and tightened the cadence line.
3. 4.5 — Contraindications, protocol and qualitative items tightened: Compressed the CKD and AV-block gates, the three protocol sub-lines, the first time-to-effect sub-line and four qualitative markers without dropping any item or qualifier.

Issues 23/08/2026 02:41

1. 12.3 — Redundant “(conflicted)” qualifiers: [benefits_low] (QRS line 528) appends “(conflicted)” to “Muscle cramp relief”, “Fibromyalgia pain relief” and “Reduced subjective anxiety”; the Low tier already encodes evidence strength, so these qualifiers must be stripped.

Fixes 23/08/2026 02:41

1. 12.3 — Redundant “(conflicted)” qualifiers: Removed the three “(conflicted)” qualifiers from [benefits_low], leaving “Muscle cramp relief, fibromyalgia pain relief, reduced post-exercise muscle soreness, reduced subjective anxiety”.

Issues 23/08/2026 02:35

1. 2.5 — Imperative in interaction item: The first [caution_items] entry (line 553) reads “separate at least two hours before or four hours after”, an instruction to the reader rather than presented information; the sibling items all use nominal or passive forms.
2. 10.4 — Action 2 sourced outside Protocol: [action_2_value] “Split, with food” (line 458) and [action_2_sub] “Two or three smaller doses with meals” (line 461) derive from the ER Risk Mitigation Strategies bullet, not from the Therapeutic Protocol section that item 10.4 requires.

Fixes 23/08/2026 02:35

1. 2.5 — Imperative in interaction item: Changed the first [caution_items] entry from the imperative “separate at least two hours before or four hours after” to the nominal “separation of at least two hours before or four hours after”, matching the ER wording and the sibling items.
2. 10.4 — Action 2 sourced outside Protocol: Replaced [action_2_value] “Split, with food” with “Split dosing preferred” and [action_2_sub] “Two or three smaller doses with meals; fractional absorption falls…” with “Fractional absorption falls as single-dose size rises and tolerance improves; the benefit is tolerability.”, so both derive solely from the ER Therapeutic Protocol section.